Skip to content
Screener

Supernus Pharmaceuticals SUPN Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$1.59M0.0%
XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$316K-80.4%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$62.95M+13.5%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.74B+20.4%
Enterprise value$2.59B+19.9%
P/S3.5×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cost of revenues(a)23,39115,763
Research and development39,43826,927
Selling, general and administrative125,17389,944
Amortization of intangible assets25,64419,786
Contingent consideration loss2,3917,660
Total costs and expenses216,037160,080
Operating loss(8,332)(10,256)
Other income (expense)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets?
Supernus Pharmaceuticals (SUPN) reported amortization of capitalized software and acquired intangible assets of $25.64M in Q1 2026.
How has Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets changed year-over-year?
Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets increased by 29.6% year-over-year, from $19.79M to $25.64M.
What is the long-term trend for Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets has grown at a 31.4% compound annual growth rate (CAGR), from $29.99M to $89.46M.

Ask your AI about Supernus Pharmaceuticals's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude